Worin besteht die galenische Innovation bei Enantone® Monats-Depot?

  • R. Hübner
Conference paper


Zunächst soll in einem kurzen Abriß die Geschichte dieser Entwicklung geschildert werden.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aird CC, Matory WF (1974) Experimental evaluation of Dexon suture in the dog. H Natl Med Assoc 66: 424–425Google Scholar
  2. 2.
    Anik S et al. (1984) Nasal absorption of nafarelin acetate, the decapeptide [D-Nal(2)6] LHRH, in rhesus monkeys. I. J Pharm Sci 73: 684–685CrossRefGoogle Scholar
  3. 3.
    Arimura A et al. (1979) Reduction of testicular luteinizing hormone/human chlorionic gonadotropin receptors by [D Trp6]-luteinizing hormone releasing hormone in hypophysectomized rats. Biochem Biophys Res Commun 90 (3): 687–693PubMedCrossRefGoogle Scholar
  4. 4.
    Conn J jr et al. (1974) Vicryl (Polyglactin 910) synthetic absorbable sutures. Am J Surg 128: 142–152CrossRefGoogle Scholar
  5. 5.
    Cutright DE et al. (1981) Histologic comparison of polylactic and polyglycolic acid sutures. Oral Surg 32: 165–173CrossRefGoogle Scholar
  6. 6.
    Eisenberger MA et al. (1986) Gondotropin hormone-releasing hormone analogues: a new therapeutic approach for prostatic carcinoma. J Clin Oncol 4 (3): 414–424PubMedGoogle Scholar
  7. 7.
    Harris GW (1948) Neural Control of the Pituitary Gland. Physiol Rev 28 (2): 139–179PubMedGoogle Scholar
  8. 8.
    Huggins C et al. (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 293–297Google Scholar
  9. 9.
    Kulkarni DE et al. (1966) Polylactic acid for surgical implants. Arch Surg 93: 839–843PubMedGoogle Scholar
  10. 10.
    Matsuo H et al. (1981) Structure of the Porcine LH- and FSHreleasing-hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 43 (6): 1334–1339CrossRefGoogle Scholar
  11. 11.
    Mazzei Tet al. (1990) Human pharmacokinetic and pharmacodynamic profiles of leuprorelin acetate depot in prostatic cancer patients. J Intern Med Res 18 (Suppl 1): 42–56Google Scholar
  12. 12.
    OgawaYet al. (1989) Controlled release of LHRH agonist, leuprolide acetate, from microcapsules: serum drug level profiles and pharmacological effects in animals. J Pharm Pharmacol 41: 439–444PubMedCrossRefGoogle Scholar
  13. 13.
    Pasimeni A (1976) Ricerche sull’attivita’ teratogena e cancerogena di un materiale du sutura sintetica: il „dexon green“.. Studi Urbinati-Serie di Farmacia 49: 173–194Google Scholar
  14. 14.
    Pasimeni A (1976) Ricerche tossicologiche su un materiale di satura sintetica: il „dexon green“. Studi Urbinati-Serie di Farmacia 49: 195–221Google Scholar
  15. 15.
    Schally AV et al. (1985) New approaches to treatment of hormone dependent prostate and mammary tumors with LH-RH analogs. In: Movin RJ, Bing RJ (eds) Frontiers in Medicine. Implications for the Future. Human Sciences Press, New York, pp 165–185Google Scholar
  16. 16.
    Shimamoto T et al. (1987) Pharmaceutical aspects. Nasal and depot formulation of leuprorelide. J Androl 8 (1): 14–16Google Scholar
  17. 17.
    Vischer GE et al. (1985) Biodegradation of and tissue reaction to 50:50 poly(DL-lactide-co-glycolide) microcapsules. J Biomed Mat Res 19: 349–365CrossRefGoogle Scholar
  18. 18.
    Wise D et al. (1976) Sustained release of an antimaterial drug using a copolymer of glycolic lactic acid. Life Sci 19: 867–874PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • R. Hübner

There are no affiliations available

Personalised recommendations